載入...
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunothe...
Na minha lista:
| 發表在: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499002/ https://ncbi.nlm.nih.gov/pubmed/28679395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0506-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|